Stockreport

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Denali Therapeutics Inc.  (DNLI) 
Last denali therapeutics inc. earnings: 8/6 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.denalitherapeutics.com
PDF FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025Pre [Read more]